drugset / Trial / NCT00483470

Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster Dose

NCT00483470

Phase 3 Completed 720 enrolled Sanofi Pasteur, a Sanofi Company
RandomizedParallel-groupOpen-labelPrevention

Summary

As per request by the Heath Authorities, the present clinical study will assess the immunogenicity and safety

Timeline

Start
2007-06
Primary completion
2008-05
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator HAVRIX 720 Vaccine 0.5 ml Intramuscular
Subject Varicella vaccine Vaccine 0.5 ml Intramuscular